

# Global Neuroendocrine Tumor Drug Market Insight and Forecast to 2026

<https://marketpublishers.com/r/G4F2F137086EEN.html>

Date: August 2020

Pages: 169

Price: US\$ 2,350.00 (Single User License)

ID: G4F2F137086EEN

## Abstracts

The research team projects that the Neuroendocrine Tumor Drug market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Eisai

Jiangsu Hengrui Medicine Co., Ltd.

Hutchison MediPharma Limited

Exelixis, Inc.

Ipsen S.A.

Foresee Pharmaceuticals, LLC

Lexicon Pharmaceuticals, Inc.

INVENT Pharmaceuticals, Inc.

Intezyne, Inc

Karyopharm Therapeutics, Inc.

Novartis AG  
Midatech Pharma Plc .  
OctreoPharm Sciences GmbH  
Northwest Biotherapeutics, Inc.  
Millennium Pharmaceuticals, Inc.  
OXiGENE, Inc.  
MolMed S.p.A.

#### By Type

mTOR protein inhibitors  
Tyrosine kinase 3 inhibitors  
Somatostatin receptor antagonists  
Growth hormone releasing factor antagonists  
Somatostatin receptor agonists  
Others

#### By Application

Hospital  
Clinic  
Others

#### By Regions/Countries:

North America  
United States  
Canada  
Mexico

#### East Asia

China  
Japan  
South Korea

#### Europe

Germany  
United Kingdom  
France  
Italy

#### South Asia

India

Southeast Asia

Indonesia

Thailand

Singapore

Middle East

Turkey

Saudi Arabia

Iran

Africa

Nigeria

South Africa

Oceania

Australia

South America

### Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

### Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Neuroendocrine Tumor Drug 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2019.

#### Key Indicators Analysed

**Market Players & Competitor Analysis:** The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

**Global and Regional Market Analysis:** The report includes Global & Regional market status and outlook 2021-2026. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

**Market Analysis by Product Type:** The report covers majority Product Types in the Neuroendocrine Tumor Drug Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

**Market Analysis by Application Type:** Based on the Neuroendocrine Tumor Drug Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

**Market Trends:** Market key trends which include Increased Competition and Continuous Innovations.

**Opportunities and Drivers:** Identifying the Growing Demands and New Technology

**Porters Five Force Analysis:** The report will provide with the state of competition in

industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

#### COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neuroendocrine Tumor Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Neuroendocrine Tumor Drug Revenue

1.4 Market Analysis by Type

1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 mTOR protein inhibitors

1.4.3 Tyrosine kinase 3 inhibitors

1.4.4 Somatostatin receptor antagonists

1.4.5 Growth hormone releasing factor antagonists

1.4.6 Somatostatin receptor agonists

1.4.7 Others

1.5 Market by Application

1.5.1 Global Neuroendocrine Tumor Drug Market Share by Application: 2021-2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.6.2 Covid-19 Impact: Commodity Prices Indices

1.6.3 Covid-19 Impact: Global Major Government Policy

1.7 Study Objectives

1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS

2.1 Global Neuroendocrine Tumor Drug Market Perspective (2021-2026)

2.2 Neuroendocrine Tumor Drug Growth Trends by Regions

2.2.1 Neuroendocrine Tumor Drug Market Size by Regions: 2015 VS 2021 VS 2026

2.2.2 Neuroendocrine Tumor Drug Historic Market Size by Regions (2015-2020)

2.2.3 Neuroendocrine Tumor Drug Forecasted Market Size by Regions (2021-2026)

### 3 MARKET COMPETITION BY MANUFACTURERS

3.1 Global Neuroendocrine Tumor Drug Production Capacity Market Share by Manufacturers (2015-2020)

3.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2015-2020)

3.3 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2015-2020)

## **4 NEUROENDOCRINE TUMOR DRUG PRODUCTION BY REGIONS**

### 4.1 North America

4.1.1 North America Neuroendocrine Tumor Drug Market Size (2015-2026)

4.1.2 Neuroendocrine Tumor Drug Key Players in North America (2015-2020)

4.1.3 North America Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

4.1.4 North America Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

### 4.2 East Asia

4.2.1 East Asia Neuroendocrine Tumor Drug Market Size (2015-2026)

4.2.2 Neuroendocrine Tumor Drug Key Players in East Asia (2015-2020)

4.2.3 East Asia Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

4.2.4 East Asia Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

### 4.3 Europe

4.3.1 Europe Neuroendocrine Tumor Drug Market Size (2015-2026)

4.3.2 Neuroendocrine Tumor Drug Key Players in Europe (2015-2020)

4.3.3 Europe Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

4.3.4 Europe Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

### 4.4 South Asia

4.4.1 South Asia Neuroendocrine Tumor Drug Market Size (2015-2026)

4.4.2 Neuroendocrine Tumor Drug Key Players in South Asia (2015-2020)

4.4.3 South Asia Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

4.4.4 South Asia Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

### 4.5 Southeast Asia

4.5.1 Southeast Asia Neuroendocrine Tumor Drug Market Size (2015-2026)

4.5.2 Neuroendocrine Tumor Drug Key Players in Southeast Asia (2015-2020)

4.5.3 Southeast Asia Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

4.5.4 Southeast Asia Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

### 4.6 Middle East

4.6.1 Middle East Neuroendocrine Tumor Drug Market Size (2015-2026)

4.6.2 Neuroendocrine Tumor Drug Key Players in Middle East (2015-2020)

4.6.3 Middle East Neuroendocrine Tumor Drug Market Size by Type (2015-2020)

- 4.6.4 Middle East Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
- 4.7 Africa
  - 4.7.1 Africa Neuroendocrine Tumor Drug Market Size (2015-2026)
  - 4.7.2 Neuroendocrine Tumor Drug Key Players in Africa (2015-2020)
  - 4.7.3 Africa Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
  - 4.7.4 Africa Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
- 4.8 Oceania
  - 4.8.1 Oceania Neuroendocrine Tumor Drug Market Size (2015-2026)
  - 4.8.2 Neuroendocrine Tumor Drug Key Players in Oceania (2015-2020)
  - 4.8.3 Oceania Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
  - 4.8.4 Oceania Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
- 4.9 South America
  - 4.9.1 South America Neuroendocrine Tumor Drug Market Size (2015-2026)
  - 4.9.2 Neuroendocrine Tumor Drug Key Players in South America (2015-2020)
  - 4.9.3 South America Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
  - 4.9.4 South America Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
- 4.10 Rest of the World
  - 4.10.1 Rest of the World Neuroendocrine Tumor Drug Market Size (2015-2026)
  - 4.10.2 Neuroendocrine Tumor Drug Key Players in Rest of the World (2015-2020)
  - 4.10.3 Rest of the World Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
  - 4.10.4 Rest of the World Neuroendocrine Tumor Drug Market Size by Application (2015-2020)

## **5 NEUROENDOCRINE TUMOR DRUG CONSUMPTION BY REGION**

- 5.1 North America
  - 5.1.1 North America Neuroendocrine Tumor Drug Consumption by Countries
  - 5.1.2 United States
  - 5.1.3 Canada
  - 5.1.4 Mexico
- 5.2 East Asia
  - 5.2.1 East Asia Neuroendocrine Tumor Drug Consumption by Countries
  - 5.2.2 China
  - 5.2.3 Japan
  - 5.2.4 South Korea
- 5.3 Europe



### 5.3.1 Europe Neuroendocrine Tumor Drug Consumption by Countries

5.3.2 Germany

5.3.3 United Kingdom

5.3.4 France

5.3.5 Italy

5.3.6 Russia

5.3.7 Spain

5.3.8 Netherlands

5.3.9 Switzerland

5.3.10 Poland

### 5.4 South Asia

5.4.1 South Asia Neuroendocrine Tumor Drug Consumption by Countries

5.4.2 India

5.4.3 Pakistan

5.4.4 Bangladesh

### 5.5 Southeast Asia

5.5.1 Southeast Asia Neuroendocrine Tumor Drug Consumption by Countries

5.5.2 Indonesia

5.5.3 Thailand

5.5.4 Singapore

5.5.5 Malaysia

5.5.6 Philippines

5.5.7 Vietnam

5.5.8 Myanmar

### 5.6 Middle East

5.6.1 Middle East Neuroendocrine Tumor Drug Consumption by Countries

5.6.2 Turkey

5.6.3 Saudi Arabia

5.6.4 Iran

5.6.5 United Arab Emirates

5.6.6 Israel

5.6.7 Iraq

5.6.8 Qatar

5.6.9 Kuwait

5.6.10 Oman

### 5.7 Africa

5.7.1 Africa Neuroendocrine Tumor Drug Consumption by Countries

5.7.2 Nigeria

5.7.3 South Africa

- 5.7.4 Egypt
- 5.7.5 Algeria
- 5.7.6 Morocco
- 5.8 Oceania
  - 5.8.1 Oceania Neuroendocrine Tumor Drug Consumption by Countries
  - 5.8.2 Australia
  - 5.8.3 New Zealand
- 5.9 South America
  - 5.9.1 South America Neuroendocrine Tumor Drug Consumption by Countries
  - 5.9.2 Brazil
  - 5.9.3 Argentina
  - 5.9.4 Columbia
  - 5.9.5 Chile
  - 5.9.6 Venezuela
  - 5.9.7 Peru
  - 5.9.8 Puerto Rico
  - 5.9.9 Ecuador
- 5.10 Rest of the World
  - 5.10.1 Rest of the World Neuroendocrine Tumor Drug Consumption by Countries
  - 5.10.2 Kazakhstan

## **6 NEUROENDOCRINE TUMOR DRUG SALES MARKET BY TYPE (2015-2026)**

- 6.1 Global Neuroendocrine Tumor Drug Historic Market Size by Type (2015-2020)
- 6.2 Global Neuroendocrine Tumor Drug Forecasted Market Size by Type (2021-2026)

## **7 NEUROENDOCRINE TUMOR DRUG CONSUMPTION MARKET BY APPLICATION(2015-2026)**

- 7.1 Global Neuroendocrine Tumor Drug Historic Market Size by Application (2015-2020)
- 7.2 Global Neuroendocrine Tumor Drug Forecasted Market Size by Application (2021-2026)

## **8 COMPANY PROFILES AND KEY FIGURES IN NEUROENDOCRINE TUMOR DRUG BUSINESS**

- 8.1 Eisai
  - 8.1.1 Eisai Company Profile
  - 8.1.2 Eisai Neuroendocrine Tumor Drug Product Specification

8.1.3 Eisai Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.2 Jiangsu Hengrui Medicine Co., Ltd.

8.2.1 Jiangsu Hengrui Medicine Co., Ltd. Company Profile

8.2.2 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Specification

8.2.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.3 Hutchison MediPharma Limited

8.3.1 Hutchison MediPharma Limited Company Profile

8.3.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Specification

8.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.4 Exelixis, Inc.

8.4.1 Exelixis, Inc. Company Profile

8.4.2 Exelixis, Inc. Neuroendocrine Tumor Drug Product Specification

8.4.3 Exelixis, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.5 Ipsen S.A.

8.5.1 Ipsen S.A. Company Profile

8.5.2 Ipsen S.A. Neuroendocrine Tumor Drug Product Specification

8.5.3 Ipsen S.A. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.6 Foresee Pharmaceuticals, LLC

8.6.1 Foresee Pharmaceuticals, LLC Company Profile

8.6.2 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Specification

8.6.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.7 Lexicon Pharmaceuticals, Inc.

8.7.1 Lexicon Pharmaceuticals, Inc. Company Profile

8.7.2 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Specification

8.7.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.8 INVENT Pharmaceuticals, Inc.

8.8.1 INVENT Pharmaceuticals, Inc. Company Profile

8.8.2 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product

## Specification

8.8.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.9 Intezyne, Inc

8.9.1 Intezyne, Inc Company Profile

8.9.2 Intezyne, Inc Neuroendocrine Tumor Drug Product Specification

8.9.3 Intezyne, Inc Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.10 Karyopharm Therapeutics, Inc.

8.10.1 Karyopharm Therapeutics, Inc. Company Profile

8.10.2 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Specification

8.10.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.11 Novartis AG

8.11.1 Novartis AG Company Profile

8.11.2 Novartis AG Neuroendocrine Tumor Drug Product Specification

8.11.3 Novartis AG Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.12 Midatech Pharma Plc .

8.12.1 Midatech Pharma Plc . Company Profile

8.12.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Specification

8.12.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.13 OctreoPharm Sciences GmbH

8.13.1 OctreoPharm Sciences GmbH Company Profile

8.13.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Specification

8.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.14 Northwest Biotherapeutics, Inc.

8.14.1 Northwest Biotherapeutics, Inc. Company Profile

8.14.2 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Specification

8.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 8.15 Millennium Pharmaceuticals, Inc.

8.15.1 Millennium Pharmaceuticals, Inc. Company Profile

8.15.2 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product

## Specification

8.15.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.16 OXiGENE, Inc.

8.16.1 OXiGENE, Inc. Company Profile

8.16.2 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Specification

8.16.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.17 MolMed S.p.A.

8.17.1 MolMed S.p.A. Company Profile

8.17.2 MolMed S.p.A. Neuroendocrine Tumor Drug Product Specification

8.17.3 MolMed S.p.A. Neuroendocrine Tumor Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## 9 PRODUCTION AND SUPPLY FORECAST

9.1 Global Forecasted Production of Neuroendocrine Tumor Drug (2021-2026)

9.2 Global Forecasted Revenue of Neuroendocrine Tumor Drug (2021-2026)

9.3 Global Forecasted Price of Neuroendocrine Tumor Drug (2015-2026)

9.4 Global Forecasted Production of Neuroendocrine Tumor Drug by Region (2021-2026)

9.4.1 North America Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.2 East Asia Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.3 Europe Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.4 South Asia Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.5 Southeast Asia Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.6 Middle East Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.7 Africa Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.8 Oceania Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.9 South America Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

9.4.10 Rest of the World Neuroendocrine Tumor Drug Production, Revenue Forecast (2021-2026)

## 9.5 Forecast by Type and by Application (2021-2026)

9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)

9.5.2 Global Forecasted Consumption of Neuroendocrine Tumor Drug by Application (2021-2026)

## **10 CONSUMPTION AND DEMAND FORECAST**

10.1 North America Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.2 East Asia Market Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.3 Europe Market Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.4 South Asia Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.5 Southeast Asia Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.6 Middle East Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.7 Africa Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.8 Oceania Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.9 South America Forecasted Consumption of Neuroendocrine Tumor Drug by Country

10.10 Rest of the world Forecasted Consumption of Neuroendocrine Tumor Drug by Country

## **11 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS**

11.1 Marketing Channel

11.2 Neuroendocrine Tumor Drug Distributors List

11.3 Neuroendocrine Tumor Drug Customers

## **12 INDUSTRY TRENDS AND GROWTH STRATEGY**

12.1 Market Top Trends

12.2 Market Drivers

12.3 Market Challenges

12.4 Porter's Five Forces Analysis

12.5 Neuroendocrine Tumor Drug Market Growth Strategy

## **13 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **14 APPENDIX**

### 14.1 Research Methodology

#### 14.1.1 Methodology/Research Approach

#### 14.1.2 Data Source

### 14.2 Disclaimer

## List Of Tables

### LIST OF TABLES AND FIGURES

Table 1. Global Neuroendocrine Tumor Drug Market Share by Type: 2020 VS 2026

Table 2. mTOR protein inhibitors Features

Table 3. Tyrosine kinase 3 inhibitors Features

Table 4. Somatostatin receptor antagonists Features

Table 5. Growth hormone releasing factor antagonists Features

Table 6. Somatostatin receptor agonists Features

Table 7. Others Features

Table 11. Global Neuroendocrine Tumor Drug Market Share by Application: 2020 VS 2026

Table 12. Hospital Case Studies

Table 13. Clinic Case Studies

Table 14. Others Case Studies

Table 21. Commodity Prices-Metals Price Indices

Table 22. Commodity Prices- Precious Metal Price Indices

Table 23. Commodity Prices- Agricultural Raw Material Price Indices

Table 24. Commodity Prices- Food and Beverage Price Indices

Table 25. Commodity Prices- Fertilizer Price Indices

Table 26. Commodity Prices- Energy Price Indices

Table 27. G20+: Economic Policy Responses to COVID-19

Table 28. Neuroendocrine Tumor Drug Report Years Considered

Table 29. Global Neuroendocrine Tumor Drug Market Size YoY Growth 2021-2026 (US\$ Million)

Table 30. Global Neuroendocrine Tumor Drug Market Share by Regions: 2021 VS 2026

Table 31. North America Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 32. East Asia Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 33. Europe Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 34. South Asia Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 35. Southeast Asia Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 36. Middle East Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 37. Africa Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026)



(US\$ Million)

Table 38. Oceania Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026)

(US\$ Million)

Table 39. South America Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 40. Rest of the World Neuroendocrine Tumor Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 41. North America Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 42. East Asia Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 43. Europe Neuroendocrine Tumor Drug Consumption by Region (2015-2020)

Table 44. South Asia Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 45. Southeast Asia Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 46. Middle East Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 47. Africa Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 48. Oceania Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 49. South America Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 50. Rest of the World Neuroendocrine Tumor Drug Consumption by Countries (2015-2020)

Table 51. Eisai Neuroendocrine Tumor Drug Product Specification

Table 52. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Specification

Table 53. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Specification

Table 54. Exelixis, Inc. Neuroendocrine Tumor Drug Product Specification

Table 55. Ipsen S.A. Neuroendocrine Tumor Drug Product Specification

Table 56. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Specification

Table 57. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Specification

Table 58. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Specification

Table 59. Intezyne, Inc Neuroendocrine Tumor Drug Product Specification

Table 60. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product

## Specification

Table 61. Novartis AG Neuroendocrine Tumor Drug Product Specification

Table 62. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Specification

Table 63. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Specification

Table 64. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Specification

Table 65. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Specification

Table 66. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Specification

Table 67. MolMed S.p.A. Neuroendocrine Tumor Drug Product Specification

Table 101. Global Neuroendocrine Tumor Drug Production Forecast by Region (2021-2026)

Table 102. Global Neuroendocrine Tumor Drug Sales Volume Forecast by Type (2021-2026)

Table 103. Global Neuroendocrine Tumor Drug Sales Volume Market Share Forecast by Type (2021-2026)

Table 104. Global Neuroendocrine Tumor Drug Sales Revenue Forecast by Type (2021-2026)

Table 105. Global Neuroendocrine Tumor Drug Sales Revenue Market Share Forecast by Type (2021-2026)

Table 106. Global Neuroendocrine Tumor Drug Sales Price Forecast by Type (2021-2026)

Table 107. Global Neuroendocrine Tumor Drug Consumption Volume Forecast by Application (2021-2026)

Table 108. Global Neuroendocrine Tumor Drug Consumption Value Forecast by Application (2021-2026)

Table 109. North America Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 110. East Asia Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 111. Europe Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 112. South Asia Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 113. Southeast Asia Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 114. Middle East Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 115. Africa Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 116. Oceania Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 117. South America Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 118. Rest of the world Neuroendocrine Tumor Drug Consumption Forecast 2021-2026 by Country

Table 119. Neuroendocrine Tumor Drug Distributors List

Table 120. Neuroendocrine Tumor Drug Customers List

Table 121. Porter's Five Forces Analysis

Table 122. Key Executives Interviewed

Figure 1. North America Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 2. North America Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 3. United States Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 4. Canada Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 5. Mexico Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 6. East Asia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 7. East Asia Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 8. China Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 9. Japan Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 10. South Korea Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 11. Europe Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 12. Europe Neuroendocrine Tumor Drug Consumption Market Share by Region in 2020

Figure 13. Germany Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 14. United Kingdom Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 15. France Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 16. Italy Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 17. Russia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 18. Spain Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 19. Netherlands Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 20. Switzerland Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 21. Poland Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 22. South Asia Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 23. South Asia Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 24. India Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 25. Pakistan Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 26. Bangladesh Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 27. Southeast Asia Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 28. Southeast Asia Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 29. Indonesia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 30. Thailand Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 31. Singapore Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 32. Malaysia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 33. Philippines Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 34. Vietnam Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 35. Myanmar Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 36. Middle East Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 37. Middle East Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 38. Turkey Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 39. Saudi Arabia Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 40. Iran Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 41. United Arab Emirates Neuroendocrine Tumor Drug Consumption and Growth

Rate (2015-2020)

Figure 42. Israel Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 43. Iraq Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 44. Qatar Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 45. Kuwait Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 46. Oman Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 47. Africa Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 48. Africa Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 49. Nigeria Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 50. South Africa Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 51. Egypt Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 52. Algeria Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 53. Morocco Neuroendocrine Tumor Drug Consumption and Growth Rate

(2015-2020)

Figure 54. Oceania Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 55. Oceania Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 56. Australia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 57. New Zealand Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 58. South America Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 59. South America Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 60. Brazil Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 61. Argentina Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 62. Columbia Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 63. Chile Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 64. Venezuelal Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 65. Peru Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 66. Puerto Rico Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 67. Ecuador Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 68. Rest of the World Neuroendocrine Tumor Drug Consumption and Growth Rate

Figure 69. Rest of the World Neuroendocrine Tumor Drug Consumption Market Share by Countries in 2020

Figure 70. Kazakhstan Neuroendocrine Tumor Drug Consumption and Growth Rate (2015-2020)

Figure 71. Global Neuroendocrine Tumor Drug Production Capacity Growth Rate Forecast (2021-2026)

Figure 72. Global Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 73. Global Neuroendocrine Tumor Drug Price and Trend Forecast (2015-2026)

Figure 74. North America Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 75. North America Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 76. East Asia Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 77. East Asia Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 78. Europe Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 79. Europe Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 80. South Asia Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 81. South Asia Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 82. Southeast Asia Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 83. Southeast Asia Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 84. Middle East Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 85. Middle East Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 86. Africa Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 87. Africa Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 88. Oceania Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 89. Oceania Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 90. South America Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 91. South America Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 92. Rest of the World Neuroendocrine Tumor Drug Production Growth Rate Forecast (2021-2026)

Figure 93. Rest of the World Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026)

Figure 94. North America Neuroendocrine Tumor Drug Consumption Forecast

2021-2026

Figure 95. East Asia Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 96. Europe Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 97. South Asia Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 98. Southeast Asia Neuroendocrine Tumor Drug Consumption Forecast  
2021-2026

Figure 99. Middle East Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 100. Africa Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 101. Oceania Neuroendocrine Tumor Drug Consumption Forecast 2021-2026

Figure 102. South America Neuroendocrine Tumor Drug Consumption Forecast  
2021-2026

Figure 103. Rest of the world Neuroendocrine Tumor Drug Consumption Forecast  
2021-2026

Figure 104. Channels of Distribution

Figure 105. Distributors Profiles



## I would like to order

Product name: Global Neuroendocrine Tumor Drug Market Insight and Forecast to 2026

Product link: <https://marketpublishers.com/r/G4F2F137086EEN.html>

Price: US\$ 2,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4F2F137086EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970